Publication | Closed Access

Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen

Bone DiseaseBone HealthInvolutional OsteoporosisPharmacotherapyBone DensityMedicineMg RisedronateOsteoporosisOrthopaedic SurgeryAnesthesiologyOnce-weekly Administration